HHS, Defense Department invest in manufacturing demonstration to produce 100 million COVID-19 investigational vaccine doses
The Department of Health and Human Services today announced that it will partner with the Department of Defense to fund the advanced development — including clinical trials and large-scale manufacturing — of a COVID-19 investigational vaccine from Sanofi and GlaxoSmithKline.
The investment is expected to yield 100 million fill-finished doses, meaning vaccine doses are packaged and ready to ship immediately if clinical trials are successful and the Food and Drug Administration authorizes its use.
Related News Articles
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…